Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 27, 2026
October 27, 2026
bd746678-d2ab-441f-b005-7065f4f7a403
Related Documents
Potency Assessment of Active Immunotherapy Products
Guidance DocumentAugust 19, 2026Center for Biologics Evaluation and Research
Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing
Guidance DocumentApril 14, 2026Center for Biologics Evaluation and Research
Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry
Guidance DocumentSeptember 24, 2025Center for Biologics Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.